NHI.no
Annonse
Informasjon

Langerhans-celle histiocytose

Histiocytose er en sjelden sykdom som skyldes overskudd av en type hvite blodceller kalt histiocytter. Histiocyttene klumper seg sammen og kan angripe hud, bein, lever, milt, tannkjøtt, lunger, øyne, ører og/eller sentralnervesystemet.

Langerhans-celle histiocytose rammer særlig barn, og de fleste får diagnosen mellom 1-3 års alder.

Sist oppdatert:

12. jan. 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Langerhans-celle histiocytose . Referanselisten for dette dokumentet vises nedenfor

  1. Go RS, Jacobsen E, Baiocchi R, et al. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(11):1277-1303. PubMed
  2. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672-2681. PubMed
  3. Durham BH. Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol. 2019;86:62-76. PubMed
  4. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127:2672. Blood
  5. Guyot-Goubin A, Donadieu J, Barkaoui M, et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer 2008;51:71–75.
  6. Stålemark H, Laurencikas E, Karis J, et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer 2008;51:76–81. PMID: 18266220 PubMed
  7. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375–2390.
  8. Egeler RM, van Halteren AG, Hogendoorn PC, Laman JD, Leenen PJ. Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev. Mar 2010;234(1):213-32. PubMed
  9. Shea CR. Langerhans Cell Histiocytosis. Medscape, last updated Nov 08, 2018.
  10. Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA 2017. doi:10.1001/jamaoncol.2017.5029 DOI
  11. Héritier S, Barkaoui MA, Miron J, et al. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Br J Haematol 2018;183:608–617. PMID: 30421536 PubMed
  12. Haroche J, Cohen-Aubart F, Rollins BJ, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol 2017;18:e113–e125. PMID: 28214412 PubMed
  13. Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010;156:873–881.e1. PMID: 20434166 PubMed
  14. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol. Dec 2008;8(12):935-47 PubMed
  15. Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 2013;8:72. PubMed
  16. Maghnie M, Cosi G, Genovese E, et. al. Central Diabetes Insipidus in Children and Young Adults. N Engl J Med 2000; 343: 998-1007. New England Journal of Medicine
  17. Modan-Moses D, Weintraub M, Meyerovitch J, Segal-Lieberman G, Bielora B. Hypopituitarism in langerhans cell histiocytosis: seven cases and a literature review. J Endocrinol Invest 2001; 24: 612-7. PubMed
  18. Goyal G, Young JR, Koster MJ, et al. The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc 2019;94:2054–2071. PMID: 31472931 PubMed
  19. Obert J, Vercellino L, Van Der Gucht A, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging 2017;44:598–610.
  20. Büchler T, Cervinek L, Belohlavek O, et al. Langerhans cell histiocytosis with central nervous system involvement: Follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer 2004; 43: 1-3. PubMed
  21. McClain KL. Treatment of Langerhans cell histiocytosis. UpToDate, last updated Apr 12, 2019. UpToDate
  22. Weitzman S, Wayn AS, Arceci R, Lipton JM, Whitlock JA, De Rossi G. Nucleoside Analogues in the Therapy of Langerhans Cell Histiocytosis: A Survey of Members of the Histiocyte Society and Review of the Literature. Med Ped Oncol 1999; 33; 476-81.
  23. Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R. Langerhans cells in Langerhans cell histocytosis express CD52 (Campath). Pediatr Blood Cancer 2005; 44: 251-5. PubMed
  24. von Stebut E, Schadmand-Fischer S, Bräuninger W, Kreft A, Doberauer C, Steinbrink K. Successful treatment of adult multisystemic Langerhans cell histiocytosis with Psoralen-UV-A, prednisolone, mercaptopurine, and vinblastine. Arch Dermatol 2008; 144: 649-53. PubMed
  25. Vourtsi A, Papadopoulos A, Moulopoulos LA, Xenellis J, Vlahos L. Langerhans cell histiocytosis with involvement of the pons: case report. Neuroradiology 1998; 40: 161-3. PubMed
  26. Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008;50(1):72 . pmid: 17455311 PubMed
  27. Hund E, Steiner H, Jansen O, Sieverts H, Sohl G, Essig M. Treatment of cerebral Langerhans cell histiocytosis. J Neurol Sci 1999; 171: 145-52. PubMed
  28. Gadner H, Grois N, Arico N, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001; 138: 728-34. PubMed
Annonse
Annonse